Status:
WITHDRAWN
Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia
Lead Sponsor:
Biotechnology Institute IMASD
Conditions:
Androgenetic Alopecia
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
* Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals. * This cli...
Eligibility Criteria
Inclusion
- Androgenetic alopecia according to the following scales:
- Men: Hamilton/Norwood Scale: grades II-VI
- Women: Ludwig Scale grades I-II.
- Possibility of follow-up during the study
Exclusion
- No androgenetic alopecia
- Telogen and anagen effluvium
- Active inflammation or infection in the intervention area
- Presence of active systemic infections.
- Background of cancerous or precancerous lesions.
- Background of connective or rheumatic diseases.
- Suffering from any serious blood disorders.
- To have undergone treatments for alopecia in the previous 6 months.
- Previous hair implants
- Intake of drugs that affect hair loss.
- Be undergoing immunosuppressive therapy and/or anticoagulants.
- Known intolerance to mesotherapy.
- Taking contraceptives containing cyproterone acetate.
- Pregnancy
- In general, any limitations that would prevent the proper application of both treatments and the right monitoring of the efficacy variables.
Key Trial Info
Start Date :
September 16 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2017
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01885676
Start Date
September 16 2013
End Date
December 18 2017
Last Update
February 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Clínica Eduardo Anitua.
Vitoria-Gasteiz, Alava, Spain, 01007
2
Centro dermatológico estético
Alicante, Spain, 03014